Business
SciSparc Advances Its Phase IIb Clinical Trial in Patients with Tourette Syndrome with its Proprietary Drug Candidate SCI-110
The Dual-Site Study Will Be Conducted at the Hannover Medical School in Germany, and Israel's Tel-Aviv Sourasky Medical Center TEL AVIV, Israel, Jan. 18, 2022
About this update from Scisparc Ltd.
[{"type":"text","content":"The Dual-Site Study Will Be Conducted at the Hannover Medical School in Germany, and Israel's Tel-Aviv Sourasky Medical Center\n\n\nTEL AVIV, Israel, Jan. 18, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the \"Company\" or \"SciSparc\"), today announced that it has entered into an agreement with two clinical sites: Hannover Medical School in Hannover, Germany, and Tel-Aviv Sourasky Medical School, in Tel-Aviv, Israel, to further its Phase IIb clinical study for SCI-110, the Company's proprietary drug candidate, for patients suffering from Tourette syndrome (the \"Study\" or the \"Trial\"). The trial will be conducted at the two sites. \nThe Study's Principal Investigator is Dr. Kirsten Müller-Vahl, Professor, Managing Senior Physician at the Clinic for Psychiatry, Social Psychiatry and Psychotherapy, and Director of the Tourette Outpatient Clinic at Hannover Medical School. \nThe Study's Principal Investigator at the Tel-Aviv Sourasky Medical Center is Dr. Tanya Gurevich, Director of the Movement Disorders Unit at the Sourasky Medical Center and Professor at the Sackler School of Medicine, Tel-Aviv University,\nDr. Adi Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc, stated, \"We are thrilled and honored to be partnering with both of these distinguished organizations. Dr Müller-Vahl is a world-renowned authority in cannabinoid-based therapeutics and Tourette syndrome; Dr. Gurevich is a recognized expert in movement disorders and autonomic disturbances, who has researched the impact of cannabinoids on patients with these conditions. Their insight and expertise will be invaluable as we move through this process.\"\n\"I am quite optimistic that this Study's findings will support our previous research led by Prof. Michael Bloch, Associate Professor in the Child Study Center at Yale Medical School of Medicine, USA, which showed indications that SCI-110 is potentially a safe and efficacious medication for this highly debilitating disease, and I am hopeful that it will advance our effort to create a viable therapeutic protocol for Tourette syndrome, a condition for which there is currently no effective treatment,\" Dr. Zuloff-Shani concluded. \nDr. Müller-Vahl commented on the ann...